Pharmacoeconomic impact of use of the probiotic Lactobacillus reuteri DSM 17938 for prevention of necrotizing enterocolitis in extremely low-birth-weight infants

Mary Ann VT Dimaguila1 Women’s Hospital of Greensboro, Cone Health, Greensboro, NC, USA;2 Piedmont Neonatology, Greensboro, NC, USA

Peter Gal1 Women’s Hospital of Greensboro, Cone Health, Greensboro, NC, USA;3 Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;4 Greensboro Area Health Education Center, Greensboro, NC, USACorrespondence[email protected]

Tiffany Wilson1 Women’s Hospital of Greensboro, Cone Health, Greensboro, NC, USA

John E Wimmer Jr1 Women’s Hospital of Greensboro, Cone Health, Greensboro, NC, USA;2 Piedmont Neonatology, Greensboro, NC, USA

McCrae Smith1 Women’s Hospital of Greensboro, Cone Health, Greensboro, NC, USA;2 Piedmont Neonatology, Greensboro, NC, USA

Rita Q Carlos1 Women’s Hospital of Greensboro, Cone Health, Greensboro, NC, USA;2 Piedmont Neonatology, Greensboro, NC, USA

Christie C Davanzo1 Women’s Hospital of Greensboro, Cone Health, Greensboro, NC, USA;2 Piedmont Neonatology, Greensboro, NC, USA

J Laurence Ransom1 Women’s Hospital of Greensboro, Cone Health, Greensboro, NC, USA;2 Piedmont Neonatology, Greensboro, NC, USA

show all

Pharmacoeconomic impact of use of the probiotic Lactobacillus reuteri DSM 17938 for prevention of necrotizing enterocolitis in extremely low-birth-weight infants

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pharmacoeconomic impact of use of the probiotic Lactobacillus reuteri DSM 17938 for prevention of necrotizing enterocolitis in extremely low-birth-weight infants

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date